

MEDIA RELEASE

9 May 2022

ARTRYA SIGNS FIRST U.S. HOSPITAL CLINICAL PARTNERSHIP

Initial agreement includes comparison study of patient cardiac CT scans read by experts to those read by AI-based technology

- Contracts executed to commence retrospective clinical trial in the USA
- Significant market entry step into the USA, which represents 42% of the global healthcare market¹
- Clinical Advisory Board composition completed with the appointment of Dr John (Jack) Lewin

PERTH, AUSTRALIA., (May 9, 2022) – Artrya Limited (ASX: AYA, Artrya or the Company), creator of the AI-based cardiac software solution Artrya Salix, today announces its first U.S. clinical partnership with Alabama-based Huntsville Heart Center, Inc, a national leader in coronary computed tomography angiography (CCTA) that treats more than 80,000 cardiac patients per year (www.theheartcenter.md).

As part of the initial agreement, Heart Center Research, LLC, a division of Huntsville Heart Center, will conduct a study to determine the efficacy of Artrya's technology. The multi-scanner retrospective study will utilise Artrya's core solution Salix Coronary Anatomy, a fast and effective AI-based technology capable of analysing cardiac CT scans to report a unique combination of coronary disease biomarkers, including components of high-risk plaque.

In the study, Heart Center researchers will utilise CT scans that were previously obtained for indicated clinical purposes. The scans will be anonymised and uploaded to cloud-based Salix, which will automatically interpret the scans using Artrya-proprietary software. The interpretation will then be compared with the interpretation of multiple expert readers.

Cardiologist and principal investigator of the study, Michael L. Ridner, MD, said: "I am delighted and honoured to lead a team of Heart Center physicians who will compare the heart scans of patients to see if we can validate the accuracy of Artrya Salix AI software in identifying coronary artery disease and specifically high-risk plaque as compared to human readers."

"AI technology like this holds the potential to change the way we practice medicine, and in this instance, may help us save lives. The Heart Center team is excited to be on the ground floor in evaluating Artrya's potential."

Artrya USA Co-CEO's, Jory Tremblay and Ted Schwab, said: "This is the Company's first clinical partnership in the U.S., and we are pleased that such a well-regarded heart centre has joined in our mission to create better detection of the world's leading killer -- heart disease."

"This clinical trial should be completed by October this year and will provide validation of the technology and pave the way for its commercial use in the USA."

¹ World Health Organisation, 2022

Artrya also today announces that Dr John (Jack) Lewin, former CEO of the American College of Cardiology representing over 40,000 cardiologists across the United States, has joined the Artrya Clinical Advisory Board. The Clinical Advisory Board is chaired by renowned healthcare executive Dr. Jacques J. Sokolov.

About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The Company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

Artrya USA is a wholly owned subsidiary of Artrya Limited.

For more information: www.artrya.com.

Media Enquiries:

Felicity Heath
Daymark
0457 196 603
felicity.heath@daymark.com.au

Investor Enquiries:

John Barrington
Artrya Limited
investors@artrya.com

-Ends-